seve333, thanks for the response. I know AMRN has not had much or any positive news as of recent and the investor conference was simply a regurgitation of old news. I have not sold any shares and continue on with the belief that this will get turned around in 2025 and early 26. There are several things that should / could occur in the next few months.
Italy
France
Favorable verdict on sending the Hikma case to a jury trial. I know it will play out over 2-3 years, but just the case being remanded back to a jury trial is positive and hopefully would be seen as such by the market.
Exponential Ramp-up in Europe and China
Updated Vasepa product for US
Possible Vasepa generic for US (although I don't see a benefit) as the product / price is still the product / price. Not sure if simply the word generic wins the battle.
BB
Sarrisa adding shares
I for one don't want to see a RS. What would that look like? 1 for 3, 5, 10?
Anyway, just spitballing some of the things we know are options or being worked as sit in the dark with no communications from Amarin or Sarissa.
GLTA
Market Data 
Markets 
AI
